BioSpace News Archive

Testing represents the first crucial step towards identifying a medical problem and determining the optimal treatment regimen.

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study analyzing cerebrospinal fluid (CSF) samples in patients with primary lung or breast cancer with either brain or leptomeningeal disease

Drug of abuse testing is the detection of one or more illegal and/or prescribed substances in the urine, blood, saliva, hair, or sweat.

The medical devices cuff is a replacement cuff that can be used in combination with a blood pressure monitor that is not invasive. It jointly assess blood pressure and pulse rhythm. An incorporated antimicrobial is utilized in this special cuff.

Tissue sections from organs were prepared by hand with knives or razor blades at the beginning of histology.

Medical device outsourcing is the practice or profession of recruiting a third party for various business performances such as management, manufacturing, and demand and supply chain management, product designing, among others.

A rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain is known as adrenoleukodystrophy (ALD).

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it will host a key opinion leader call on genetic hearing loss in children on Wednesday, December 2, 2020 at 8:00am Eastern Time.

ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for loncastuximab tesirine (Lonca)

THINK Surgical, an innovator in the field of orthopedic active robot surgery, announced today that the Food and Drug Administration (FDA) has cleared the second-generation of the TSolution One Total Knee Application